ScheBo SARS-CoV-2 Quick

The ScheBo® • SARS-CoV-2 Quick™ is a combined immunochromatographic lateral flow test for the simultaneous detection of SARS-CoV-2 IgM and IgG antibodies.

Effective Device:

• Combined antibody test for the simultaneous detection of SARS-CoV-2 IgM and IgG.
• Sample material: whole blood, serum or plasma.
• Rapid test results after 15 minutes.
• CE approval as medical device.
• No additional equipment needed.

 

 

Description

INTENDED USE

The ScheBo® • SARS-CoV-2 Quick™ is a visual immunochromatographic rapid test for the qualitative detection of SARS-CoV-2 IgM- and IgG-antibodies from human serum, plasma and whole blood samples. It is an in-vitro diagnostic test exclusively for professional use.
The ScheBo® • SARS-CoV-2 Quick™ is an aid in the diagnosis of a SARS-CoV-2 infection and for its early adaptive immune respond.
At the end of December 2019, Chinese public health authorities reported several cases of acute respiratory syndrome in Wuhan City, Hubei province, China. Chinese scientists soon identified a novel coronavirus as the main causative agent. The disease is now referred to as Coronavirus Disease 2019 (COVID-19), and the causative virus is called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is a new strain of coronavirus that has not been previously identified in humans. The most common signs of infection are fever, cough, shortness of breath, muscle / joint pain, sore throat, headache, nausea and vomiting. In more severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure and even death. The main transmission takes place via droplets which arise when coughing and sneezing. These droplets are absorbed by the other person through the mucous membranes of the nose, mouth and possibly the eye. A transmission through contaminated surfaces cannot be ruled out, especially in the immediate vicinity of the infected person.